Abstracts tagged "Cancer treatments and osteoporosis"

Abstract Number: 1221 • 2017 ACR/ARHP Annual Meeting
Differences in BONE Metabolism between Intermittent and Continuous Treatment with LHRH Agonists in Prostate Cancer Patients
Karla Arevalo Ruales¹, Jose Ivorra Cortes¹, Cesar David Vera Donoso², Elena Grau Garcia¹, Cristina Alcañiz Escandell¹, Ines Canovas Olmos¹, Inmaculada Chalmeta Verdejo¹, Carlos Feced Olmos¹, Jorge Juan Fragio Gil¹, Roxana Gonzalez Mazario¹, Luis Gonzalez Puig¹, Eztizen Labrador Sanchez¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz-Sanjuán¹, Elvira Vicens Bernabeu¹, David Hervás Marín³, Marta De la Rubia Navarro¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Urology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ³Biostatistics Unit. IIS La Fe, Valencia, Spain
Background/Purpose: Prostate cancer is the most common male malignancy. It is hormone dependent and androgenic inhibition with LHRH agonists is one of the mainstays of…
Abstract Number: 357 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment
Juan Carlos Ordoñez¹, Salvador López-Salguero¹, Laura Ranieri¹, Mariano Andrés^1,2, Jose Ponce³ and Isabel Ibero¹, ¹RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³ONCOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain
Background/Purpose: Women with breast cancer are at an increased risk for the development of bone loss and osteoporosis mainly due to adjuvant therapies, such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].